SCHEMBL19575679

SCHEMBL19575679

CC(C)CNc1nc(N)c2ncn(CCCCOC(=O)NCc3ccc4c(c3)OCO4)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ ADORA2B P29275 2/20 0.41
▸ HPGD P15428 4/20 0.40
▸ ALDH1A1 P00352 4/20 0.40
▸ HTT P42858 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ GAA P10253 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ ADORA2A P29274 2/20 0.40
▸ ADORA1 P30542 2/20 0.40
▸ S1PR2 O95136 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ CDK1 P06493 1/20 0.40
▸ TMIGD3 P0DMS9 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TP53 P04637 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26213491 0.91 CDK1 (0.44) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19555217 0.90 TDP1 (0.49) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19574929 0.87 TDP1 (0.56) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19575678 0.87 TDP1 (0.46) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19553567 0.86 TDP1 (0.49) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19574921 0.86 TDP1 (0.49) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19554935 0.85 TDP1 (0.49) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL20946433 0.84 TDP1 (0.48) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19575537 0.84 TDP1 (0.46) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1
SCHEMBL19553523 0.83 TDP1 (0.47) TDP1SMN1; SMN2ADORA2BHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3452477-B1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B C I PHARMA (BE) 2023-09-13 — — EP disclosed
US-11236093-B2 Adenine derivatives as protein kinase inhibitors B.C.I. PHARMA (BE) 2022-02-01 — — US disclosed
US-20190127379-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS B.C.I. PHARMA (BE) 2019-05-02 — — US disclosed
WO-2017191297-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS BCI PHARMA (FR) 2017-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236093-B2 Adenine derivatives as protein kinase inhibitors ADK, TNNI3K, TNK2 TDP1 1738/4885SMN1; SMN2 2198/4885ADORA2B 234/4885
US-20190127379-A1 ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS ADK, TNNI3K, TNK2 TDP1 1738/4885SMN1; SMN2 2198/4885ADORA2B 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback